CEO & CMO, The Jacobs Institute | Neurosurgeon & Vice-Chair, UB Neurosurgery | Director Neurological Stroke Service, Kaleida Health | Professor & Researcher, State University of New York at Buffalo
Western New York Vascular Society.
American Association of Neurological Surgery/Congress of Neurological Surgery.
Millard Fillmore Gates Hospital, Kaleida Health.
Health Sciences Institutional Review Board Committee A, University at Buffalo.
Board of Inter-Societal Accreditation of Vascular Laboratories.
American Heart Association; American Society of Neuroimaging.
Council of State Neurosurgical Societies (CSNS).
Society of Neurointerventional Surgery.
Western New York Vascular Society.
Dr. Adnan H. Siddiqui, is Professor and Vice Chairman in the Department of Neurosurgery (UBNS) at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences. He joined UBNS in December 2006. Dr. Siddiqui completed fellowship training in Interventional Neuroradiology, Cerebrovascular Surgery and Neurocritical Care from Thomas Jefferson University in Philadelphia. He completed his Neurosurgical residency at Upstate Medical University and received his PhD in Neuroscience from the University of Rochester and medical degree from Aga Khan University in Pakistan. He is a Fellow of the American Association of Neurological Surgeons, American College of Surgeons and American Heart Association. He is profoundly indebted to his mentors Nick Hopkins, Robert Rosenwasser, Charles Hodge and Shirley Joseph in shaping his career as a dual-trained cerebrovascular surgeon, clinician scientist and entrepreneur.
Dr. Siddiqui has special interest and expertise in the performance of complementary microsurgical, radiosurgical and endovascular techniques for the comprehensive management of cerebrovascular conditions. This spectrum of disease includes aneurysms and arteriovenous malformations, as well as dural, cavernous and spinal fistulae. He has special interests in endovascular management of acute ischemic stroke, as well as endovascular and microsurgical management of extracranial and intracranial vascular occlusive disease. Other clinical interests include endovascular management of intractable epistaxis, facial vascular malformations, head, neck, and brain tumor embolization and microsurgical resection of skull base tumors.
Dr. Siddiqui has over 450 peer reviewed publications, more than 50 chapters, almost 70,000 citations and an H index of 72. He is particularly proud of representing Buffalo and the US at most major cerebrovascular conferences around the world with over 200 international presentations to date. He has designed, conducted and lead multiple major national and international clinical trials and currently serves as National and International PI for multiple major funded multi-site trials. These efforts have significantly contributed to the success of the department, which was ranked 7th in academic impact in North America by the Journal of Neurosurgery.
He serves as the Chief Medical Officer at the Jacobs Institute (JI) which is focused on entrepreneurship, development and education opportunities with partners in the medical technology industry including strategics, startups and individual inventors to advance the care of patients with vascular diseases. He now assumes the role of Chief Executive Officer of the JI with the goal to improve the current offerings and translate technologies being developed at the Institute’s idea to reality (i2R) into therapeutic and commercial successes.
He leads the Canon Stroke & Vascular Research Center (CSVRC) at University at Buffalo. This multi-disciplinary center with multiple concurrent major NIH grants, houses neurosurgeons, neuroscientists, physicists and biomedical engineers working collaboratively on cutting edge research focused on neurovascular biology and pathology including stroke and aneurysms, imaging, simulation and hemodynamics. In addition, he serves as the Director of the Neurosurgical Stroke Service at the Gates Vascular Institute in Buffalo, one of the busiest Comprehensive Stroke Services in New York State and the United States.
Dr. Siddiqui has continuously served on multiple scientific and educational committees of American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS) and Society of NeuroInterventional Surgery (SNIS). He is the Chairman of the Joint Section of Cerebrovascular Surgery of the AANS and CNS and Secretary for the SNIS. It has been a major focus for him to achieve consensus between the various organizations involved in fellowship training and credentialing for Neuroendovascular Surgery. He was a founding member of the Neuroendovascular Surgery Advisory Committee (NESAC) for Society of Neurological Surgery’s Committee for Advanced Sub-specialty Training (CAST) and currently is a member of the American Board of Neurological Surgery’s (ABNS) Central Nervous System Endovascular Surgery Advisory Committee (CESAC). This has been an extremely important role, which is profoundly affecting the training and education pathways of neuroendovascular specialists.
He serves as a Neurosurgeon Director on the Executive Committee of the SNIS Patient Safety Organization which runs the NVQI-QOD Quality Outcomes Registry. He was nominated as a co-Chair for the Devices for Acute Ischemic Stroke Intervention (DAISI) a Coordinated Registry network run collaboratively by the FDA, CMS, NIH with partnership with physician societies and industry. He is committed to this singular opportunity to unify the multi-specialty neuroendovascular surgery field to develop robust prospective quality outcomes databases to shepherd the next generation of evidence-based practice. Recently, he has assumed the role of Co-Chair of the Neurological Devices Working group for the Medical Device Industry Consortium (MDIC), a not-for-profit group consisting of FDA, CMS and Industry partners dedicated to resuming Early Feasibility Studies (EFS) also known as First in man studies in the United States.
All these efforts as a microsurgeon, endovascular surgeon, scientist and trialist, have allowed Dr. Siddiqui to gain unique insights into a critical and rapidly evolving specialty. At the same time, these endeavors have required significant collaborations resulting in strong and trusting relationships with fellow neurosurgeons, neurologists, neuroradiologists, scientists, engineers, regulatory officers and industry.
Dr. Siddiqui is married and has three children. He is a proud Buffalonian who is challenged and invigorated by taking care of neurosurgical patients and their families. He is most gratified by his pedagogical responsibilities, which allow him the opportunity to teach medical students, residents and fellows. He is grateful for the opportunity to work at University at Buffalo’s Department of Neurosurgery and Canon Stroke & Vascular Research Center, Gates Vascular Institute and Jacobs Institute, facilities with some of the world’s best technologies, and greatest vascular specialists, researchers and biomedical engineers who are working together to advance the care of vascular diseases.
He worked as a thoracic and general surgeon in the north of NY and was appointed as a senior researcher in the Medical Research Institute of the New York Academy of Medical Sciences, with the main clinical focus of oesophageal surgery. He continued in this post until his move to the Seattle in the early 1992.
Dr. Siddiqui has special interest and expertise in the performance of complementary microsurgical, radiosurgical and endovascular techniques for the comprehensive management of cerebrovascular conditions. This spectrum of disease includes aneurysms and arteriovenous malformations, as well as dural, cavernous and spinal fistulae. He has special interests in acute stroke management with intra-arterial thrombolysis, as well as endovascular and microsurgical management of extracranial and intracranial vascular occlusive disease. Other clinical interests include endovascular management of intractable epistaxis; preoperative head, neck, and brain tumor embolization; resection of skull base tumors; endoscopic surgery for aneurysms and pituitary tumors; third ventriculostomy; and arachnoid cysts.
Dr. Siddiqui received the George Thorn Young Investigator Award from the School of Medicine, which is given to faculty of exceptional talent who are less than 45 years of age (2012). Dr. Siddiqui also received the Arnold P. Gold Foundation National Award for Humanism and Excellence in Teaching (2004); the National Research Service Award in Neuroscience (1996 and 1997); and the Bartlett Award, best presentation at a National Meeting, University of Rochester (1994).
Memberships
Current Research Grants: Co-investigator for NIH – 1R01EB030092-01, Project Title: High Speed Angiography at 1000 frames per second; Mentor for Brain Aneurysm Foundation Carol W. Harvey Chair of Research, Sharon Epperson Chair of Research, Project Title: A Whole Blood RNA Diagnostic for Unruptured Brain Aneurysm: Risk Assessment Prototype Development and Testing
Financial Interest/Investor/Stock Options/Ownership:
Adona Medical, Inc., Amnis Therapeutics, Bend IT Technologies, Ltd., BlinkTBI, Inc, Buffalo Technology Partners, Inc., Cardinal Consultants, LLC, Cerebrotech Medical Systems, Inc, Cerevatech Medical, Inc., Cognition Medical, CVAID Ltd., Endostream Medical, Ltd, Imperative Care, Inc., Instylla, Inc., International Medical Distribution Partners, Launch NY, Inc., NeuroRadial Technologies, Inc., Neurotechnology Investors, Neurovascular Diagnostics, Inc., PerFlow Medical, Ltd., Q’Apel Medical, Inc., QAS.ai, Inc., Radical Catheter Technologies, Inc., Rebound Therapeutics Corp. (Purchased 2019 by Integra Lifesciences, Corp), Rist Neurovascular, Inc. (Purchased 2020 by Medtronic), Sense Diagnostics, Inc., Serenity Medical, Inc., Silk Road Medical, Spinnaker Medical, Inc., StimMed, LLC, Synchron, Inc., Three Rivers Medical, Inc., Truvic Medical, Inc., Vastrax, LLC, VICIS, Inc., Viseon, Inc.
Consultant/Advisory Board:
Amnis Therapeutics, Apellis Pharmaceuticals, Inc., Boston Scientific, Canon Medical Systems USA, Inc., Cardinal Health 200, LLC, Cerebrotech Medical Systems, Inc., Cerenovus, Cerevatech Medical, Inc., Cordis, Corindus, Inc., Endostream Medical, Ltd, Imperative Care, Integra, IRRAS AB, Medtronic, MicroVention, Minnetronix Neuro, Inc., Penumbra, Q’Apel Medical, Inc., Rapid Medical, Rebound Therapeutics Corp., Serenity Medical, Inc., Silk Road Medical, StimMed, LLC, Stryker Neurovascular, Three Rivers Medical, Inc., VasSol, Viz.ai, Inc., W.L. Gore & Associates
National PI/Steering Committees:
Cerenovus EXCELLENT and ARISE II Trial; Medtronic SWIFT PRIME, VANTAGE, EMBOLISE and SWIFT DIRECT Trials; MicroVention FRED Trial & CONFIDENCE Study; MUSC POSITIVE Trial; Penumbra 3D Separator Trial, COMPASS Trial, INVEST Trial, MIVI neuroscience EVAQ Trial; Rapid Medical SUCCESS Trial;
1988 British Thoracic Society Fisons Travel Fellowship
1991 British Medical Association HC Roscoe Fellowship
1997 Royal College of Physicians Graham Bull Prize in Clinical Science
2004 North American CF Conference Plenary Lecturer (first non-American)
2005 CF Trust John Panchaud Medal